LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.55 6.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.42

Max

1.5699999999999998

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+174.15% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	137M 631M
Eelmine avamishind	-4.61
Eelmine sulgemishind	1.55

Uudiste sentiment

By Acuity

50%

155 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. märts 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2. märts 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2. märts 2026, 23:26 UTC

Uudisväärsed sündmused

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2. märts 2026, 22:41 UTC

Market Talk

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2. märts 2026, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:32 UTC

Market Talk

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2. märts 2026, 22:21 UTC

Market Talk

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

2. märts 2026, 22:11 UTC

Market Talk

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2. märts 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2. märts 2026, 22:06 UTC

Market Talk

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 22:00 UTC

Market Talk

Tulu

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

2. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. märts 2026, 21:35 UTC

Omandamised, ülevõtmised, äriostud

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2. märts 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2. märts 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 21:17 UTC

Uudisväärsed sündmused

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2. märts 2026, 20:44 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:43 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2. märts 2026, 20:28 UTC

Tulu

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2. märts 2026, 20:25 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2. märts 2026, 20:24 UTC

Tulu

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2. märts 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

2. märts 2026, 20:08 UTC

Market Talk

Uudisväärsed sündmused

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2. märts 2026, 20:05 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

174.15% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 174.15%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

155 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.